One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Pulmatrix logo
Pulmatrix PULM
$ 1.39 2.21%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Pulmatrix Balance Sheet 2026-2011 | PULM

Brief overview of Pulmatrix's assets and capital

The review uses the five latest available annual reports between 2021 and 2025.

Across five reporting periods, assets decreased -93%, from $58.8 million to $4.1 million, producing a negative trend.

Asset growth of -93% was close to the -97.1% change in liabilities, leaving the funding profile broadly stable.

Internal capital represents 92.1% of the balance sheet, previously 80.7%. This is a strong capital position.

The cash share moved from 91.5% to 98.8%. A higher figure generally provides more room in an adverse scenario.

The accumulated result is -$302.3 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

Balance sheet takeaway

Pulmatrix's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.

Annual Balance Sheet Pulmatrix

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - -10.4 M - -51.6 M -31 K -22.8 M -2.56 M -329 K 1.62 M -10.4 M -15.6 M -96 K - -

Long Term Debt

- - - 8.33 M - 857 K - - - - 3.22 M - - - - -

Long Term Debt Current

- - - 429 K 857 K 1.43 M 1.14 M 675 K - 3.22 M 2.59 M 1.03 M - - - -

Total Non Current Liabilities

- - - - - - - 7.88 M - 1 K 3.25 M - - - - -

Total Current Liabilities

905 K 329 K 929 K 3.91 M 5.02 M 4.44 M 8.25 M 17.2 M 2.88 M 5.84 M 4.65 M 3.6 M - - - -

Total Liabilities

905 K 329 K 996 K 16 M 9.84 M 11.4 M 15 K 25.1 M 2.88 M 5.84 M 7.9 M 635 K 947 K 101 K - -

Deferred Revenue

- - - 618 K 1.34 M 939 K 4.17 K 13.4 M - - - - - - - -

Retained Earnings

-303 M -302 M -297 M -288 M -273 M -255 M - -215 M -195 M -174 M -156 M -10.4 M -3.67 M -551 K -28 K -

Total Assets

4.5 M 4.14 M 9.94 M 34 M 41 M 58.8 M 38.2 K 36.1 M 14.7 M 16 M 16.7 M 10.7 M 15.6 M 148 K - -

Cash and Cash Equivalents

3.32 M 4.09 M 9.52 M 19.2 M 35.6 M 53.8 M 31.7 M 23.4 M 2.56 M 3.55 M 4.18 M 18.9 M 451 K - - -

Book Value

3.59 M 3.81 M 8.95 M 18 M 31.1 M 47.4 M 23.1 K 11 M 11.8 M 10.1 M 8.76 M 10 M 14.6 M 47 K - -

Total Shareholders Equity

3.59 M 3.81 M 8.95 M 18 M 31.1 M 47.4 M 23.1 M 11 M 11.8 M 10.1 M 8.76 M 32.6 M -78.8 M - - -

All numbers in USD currency

Quarterly Balance Sheet Pulmatrix

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - - 8.33 M 8.42 M - - - - - 430 K 857 K - - 306 K 608 K 608 K 608 K 608 K - - - - - - - - - - 1.8 M 2.52 M 3.22 M 3.22 M 3.22 M 3.22 M 5.69 M 5.69 M 5.69 M 5.69 M 39.7 M - 39.7 M - - - - - - - - - - - - -

Total Liabilities

329 K 905 K 996 K 249 K 548 K 904 K 996 K 590 K 2.47 M - 16 M 16.9 M 7.94 M 9.05 M 9.84 M 11.4 M 11 M 11.5 M 11.4 M 10.6 M 12.3 M 13.2 M 15 M 15 M 15 M 15 M 25.1 M 25.1 M 25.1 M 25.1 M 2.88 M 2.88 M 2.88 M - 5.84 M 6.54 M 7.73 M 6.89 M 7.9 M 7.9 M 7.9 M 7.9 M 12.3 M 12.3 M 12.3 M 12.3 M 44.8 M 44.8 M 44.8 M - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - 270 K - 618 K 988 K 1.11 M 1.71 M 1.34 M 1.14 M 1.56 M 1.52 M 939 K 1.97 M 3.03 M 3.14 M 4.17 M 4.17 M 4.17 M 4.17 M 13.4 M 13.4 M 13.4 M 13.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-302 M -303 M -297 M -301 M -301 M -299 M -297 M -295 M -293 M - -288 M -286 M -282 M -278 M -273 M -269 M -264 M -260 M -255 M -251 M -242 M -239 M -234 M -234 M -234 M -234 M -215 M -215 M -215 M -215 M -195 M -195 M -195 M -195 M -174 M -174 M -174 M -174 M -156 M -156 M -156 M -156 M -128 M -128 M -128 M -128 M -102 M -102 M -102 M -3.67 M - - - - - - - - - - - -

Total Assets

4.14 M 4.5 M 9.94 M 4.98 M 6.15 M 8.05 M 9.94 M 11.5 M 15.8 M - 34 M 36.8 M 31.4 M 36.1 M 41 M 46.4 M 49.4 M 54.3 M 58.8 M 55.7 M 65.4 M 69.8 M 38.1 M 38.2 M 38.2 M 38.2 M 36.1 M 36.1 M 36.1 M 36.1 M 14.7 M 14.7 M 14.7 M 14.7 M 16 M 16 M 16 M 16 M 16.7 M 16.7 M 16.7 M 16.7 M 44.9 M 44.9 M 44.9 M 44.9 M 1.55 M 1.55 M 1.55 M 15.6 M - - - - - - - - - - - -

Cash and Cash Equivalents

5.82 M 3.32 M 9.52 M 4.79 M 5.82 M 7.71 M 9.52 M 10.8 M 12.4 M 16.3 M 19.2 M 21.3 M 25.8 M 30.8 M 35.6 M 40.7 M 42.9 M 47.5 M 53.8 M 53.5 M 56.9 M 63.4 M 31.7 M 31.7 M 31.7 M 31.7 M 23.4 M 23.4 M 23.4 M 23.4 M 2.56 M 2.56 M 2.56 M 2.56 M 3.55 M 3.55 M 3.55 M 3.55 M 4.18 M 4.18 M 4.18 M 4.18 M 18.9 M 18.9 M 18.9 M 18.9 M 451 K 451 K 451 K 15.6 M 1.42 M 89 K 53 K 96 K - - - - - - - -

Book Value

3.81 M 3.59 M 8.95 M 4.73 M 5.6 M 7.15 M 8.95 M 10.9 M 13.3 M - 18 M 19.9 M 23.4 M 27 M 31.1 M 35 M 38.4 M 42.8 M 47.4 M 45.2 M 53.1 M 56.6 M 23.1 M 23.1 M 23.1 M 23.1 M 11 M 11 M 11 M 11 M 11.8 M 11.8 M 11.8 M 14.7 M 10.1 M 9.43 M 8.25 M 9.09 M 8.76 M 8.76 M 8.76 M 8.76 M 32.6 M 32.6 M 32.6 M 32.6 M -43.2 M -43.2 M -43.2 M 15.6 M - - - - - - - - - - - -

Total Shareholders Equity

8.95 M 3.59 M 18 M 4.73 M 5.6 M 7.15 M 8.95 M 10.9 M 13.3 M 19 M 18 M 19.9 M 23.4 M 27 M 31.1 M 35 M 38.4 M 42.8 M 47.4 M 45.2 M 53.1 M 56.6 M 23.1 M 23.1 M 23.1 M 23.1 M 11 M 11 M 11 M 11 M 11.8 M 11.8 M 11.8 M 11.8 M 10.1 M 10.1 M 10.1 M 10.1 M 8.76 M 8.76 M 8.76 M 8.76 M 32.6 M 32.6 M 32.6 M 32.6 M -78.8 M -78.8 M -78.8 M 14.6 M -74.8 M - - 47 K - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Pulmatrix, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.2 -0.71 % $ 651 M usaUSA
AbbVie AbbVie
ABBV
$ 293.87 0.19 % $ 520 B usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 151.6 -3.2 % $ 19.9 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 302.6 -0.19 % $ 23.6 B usaUSA
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Liquidia Corporation Liquidia Corporation
LQDA
$ 51.37 7.31 % $ 4.42 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 45.05 -9.97 % $ 4.05 B schweizSchweiz
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.48 -5.96 % $ 5.56 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.96 -3.71 % $ 640 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 62.8 1.06 % $ 128 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 7.4 -0.13 % $ 113 M australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 30.68 -1.81 % $ 2.04 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.0 -6.76 % $ 48.8 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 317.26 0.99 % $ 6.14 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 432.7 1.47 % $ 1.29 T usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.0 -3.06 % $ 16.9 B australiaAustralia
CorMedix CorMedix
CRMD
$ 5.37 -2.1 % $ 387 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
MannKind Corporation MannKind Corporation
MNKD
$ 4.22 0.84 % $ 1.29 B usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
MediciNova MediciNova
MNOV
$ 1.4 -4.76 % $ 68.7 M usaUSA
Merck & Co. Merck & Co.
MRK
$ 147.75 -0.68 % $ 370 B usaUSA
Moderna Moderna
MRNA
$ 250.79 -6.77 % $ 97.6 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 11.18 -7.72 % $ 1.21 B usaUSA
Novartis AG Novartis AG
NVS
$ 163.39 -0.18 % $ 317 B schweizSchweiz
Omeros Corporation Omeros Corporation
OMER
$ 17.3 -1.48 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 3.97 -0.75 % $ 164 M israelIsrael
Tyme Technologies Tyme Technologies
TYME
- 8.07 % $ 54 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.13 -3.22 % $ 407 M usaUSA